RxDoctor Payments Data

Darryl Hamilton, MD

Interventional Cardiology · Montgomery, ALNPI 1972537397

Payments from drug & device makers

$3,517in general payments, 2019–2025

Across 190 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$505
  • E.r. Squibb & Sons, L.L.C.$411
  • Novartis$406
  • Sanofi-aventis U.S. LLC$331
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$317
  • Pfizer$221
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,503100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,517 in reported general payments places this provider in the 25th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$78,807
Medicare patients
377
Services billed
1,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban395$358,310
EntrestoSacubitril/Valsartan183$200,490
FarxigaDapagliflozin Propanediol54$54,907
XareltoRivaroxaban53$51,007
MultaqDronedarone Hcl37$43,628
BrilintaTicagrelor61$38,759
Repatha SureclickEvolocumab13$16,606
Ranolazine ErRanolazine54$7,283
VascepaIcosapent Ethyl16$6,826
Metoprolol Succinate226$4,712
Amiodarone Hcl56$3,135
Carvedilol245$3,101
Potassium Chloride102$1,735
Isosorbide Mononitrate ErIsosorbide Mononitrate108$1,611
Hydralazine Hcl83$1,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$221$358,310395 claims
NovartisEntresto$406$200,490183 claims
AstraZenecaFarxiga, Brilinta$92$93,667115 claims
Johnson & JohnsonXarelto$45$51,00753 claims
Sanofi-aventis U.S. LLCMultaq$331$43,62837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →